Xcout IntelT-knife Therapeutics
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel T cell receptor engineered T cell therapies to fight cancer. The company is involved in biotechnology research and has a presence in Berlin, Germany.
Subscribe to see T-knife Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
T-knife Therapeutics at a glance
T-knife Therapeutics is a biotech company headquartered in Germany. Xcout tracks 12 named people at T-knife Therapeutics, including Thomas Soloway (Chief Executive Officer).
T-knife Therapeutics leadership
- Thomas SolowayChief Executive Officer
- Camille LandisChief Business Officer / Chief Financial Officer
- Peggy Sotiropoulou, Ph.D.Chief Scientific Officer
- Elisa Kieback, Ph.D.Chief Technology Officer
- Thomas Blankenstein, Ph.D.Scientific Founder of T-knife
- Michael LoveridgeVice President, Regulatory Affairs
6 more named people on record for T-knife Therapeutics, with roles, board committees and tenure — see the full roster →
T-knife Therapeutics competitors
A few of T-knife Therapeutics's closest competitors — see the full list of competitors and alternatives →
Tiankeya (also known as Beijing TCR Cure Biopharma Technology Co., Ltd.) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in China, with operations in China and the United States. The company focuses on the innovation, development, and clinical translation of engineered T cell and immune cell therapies to treat cancer and solid tumors.
T3 Pharmaceuticals AG is a biotechnology company that develops a proprietary technology platform utilizing bacteria to deliver targeted therapies. The company focuses on advancing a pipeline of Immuno-Oncology products designed to treat cancer patients.
OneChain Immunotherapeutics is a biotechnology company based in Barcelona focused on the development of CAR-T cell therapies and in vivo platforms for cancer immunotherapy.
Pan Cancer T develops pioneering T-cell receptor (TCR-T) cell therapies designed to empower patients' immune systems to target and overcome solid tumors. The company utilizes proprietary gene engineering to enhance T-cell fitness and persistence against unique cancer-specific intracellular targets.
Affini-T Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, specializing in the development of precision immunotherapies and T-cell therapies for cancer patients.
Notch Therapeutics Inc. is a private biotechnology company founded in 2018 and headquartered in Toronto, Ontario, Canada. The company specializes in the development of engineered T-cell therapies.
Get T-knife Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on T-knife Therapeutics in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access